Literature DB >> 6980624

In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.

A Gutiérrez Altés, M Díez Enciso, P Peña García, A Campos Bueno.   

Abstract

IN vitro susceptibilities of 98 isolates of Brucella melitensis to N-formimidoyl thienamycin, tetracycline, co-trimoxazole, rifampin, and cefoxitin were determined. N-Formimidoyl thienamycin showed good activity which was similar to those of tetracycline and rifampin and different from that of the other beta-lactam antibiotic tested (cefoxitin), which showed poor activity. Co-trimoxazole showed good activity.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6980624      PMCID： PMC181922          DOI： 10.1128/AAC.21.3.501

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity.

Authors:  S S Weaver; G P Bodey; B M LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

2.  Determination of the in vitro sensitivity of Brucella strains to rifampicin.

Authors:  M J Corbel
Journal:  Br Vet J       Date:  1976 May-Jun

3.  In vitro activity of thienamycin.

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

4.  In vitro susceptibility of Brucella to various antibiotics.

Authors:  W H Hall; R E Manion
Journal:  Appl Microbiol       Date:  1970-10

5.  Sensitivity of Brucella spp to tetracycline and its analogues.

Authors:  I D Farrell; P M Hinchliffe; L Robertson
Journal:  J Clin Pathol       Date:  1976-12       Impact factor: 3.411

6.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191
  6 in total
  6 in total

Review 1.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 2.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

3.  In vitro susceptibility of Brucella melitensis to antibiotics.

Authors:  E Rubinstein; R Lang; B Shasha; B Hagar; L Diamanstein; G Joseph; M Anderson; K Harrison
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

5.  In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier.

Authors:  E Palenque; J R Otero; A R Noriega
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

6.  Preparation and Evaluation of Rifampicin and Co-trimoxazole-loaded Nanocarrier against Brucella melitensis Infection

Authors:  Narges Bodaghabadi; Samira Hajigholami; Ziba Vaise Malekshahi; Maliheh Entezari; Farhood Najafi; Hadi Shirzad; Majid Sadeghizadeh
Journal:  Iran Biomed J       Date:  2017-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.